Destiny Pharma (LON:DEST) Shares Up 11.1%

Shares of Destiny Pharma plc (LON:DESTGet Free Report) traded up 11.1% during mid-day trading on Tuesday . The stock traded as high as GBX 3.94 ($0.05) and last traded at GBX 3.89 ($0.05). 1,222,156 shares traded hands during mid-day trading, an increase of 123% from the average session volume of 547,344 shares. The stock had previously closed at GBX 3.50 ($0.05).

Wall Street Analyst Weigh In

Separately, Shore Capital reiterated a “house stock” rating on shares of Destiny Pharma in a research report on Monday, July 15th.

Read Our Latest Report on Destiny Pharma

Destiny Pharma Trading Down 14.3 %

The firm’s fifty day moving average is GBX 11.53 and its 200-day moving average is GBX 28.49. The stock has a market capitalization of £2.86 million, a PE ratio of -58.33 and a beta of 0.31.

Destiny Pharma Company Profile

(Get Free Report)

Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of novel medicines to prevent serious infections in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase II clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, which is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal that is in preclinical stage for the treatment of skin infections of antibiotic resistant bacteria, as well as superficial skin infections of antibiotic resistant bacteria.

Read More

Receive News & Ratings for Destiny Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Destiny Pharma and related companies with MarketBeat.com's FREE daily email newsletter.